Otidin

Quick links to important sections

Otidin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Otidin

Quick Facts

Property Description
Active ingredient Phenazone, Tetracaine
Form Otic Solution (Ear Drops)
Pharmacological class Topical Analgesic, Local Anaesthetic, NSAID
General purpose Symptomatic relief of localized discomfort and inflammation
Origin Synthetic

Otidin: Definition and Pharmacological Classification

Otidin is a combination medicinal product specifically formulated as an otic solution (ear drops) designed for precise topical administration. It is fundamentally classified as a dual-acting topical analgesic and local anaesthetic. The formulation is characterized by the presence of its two distinct active ingredients, Phenazone and Tetracaine, which provide a comprehensive approach to localized discomfort. This preparation differs from single-entity oral systemic analgesics by delivering its therapeutic action directly to the affected site, making it clinically recognized for its targeted efficacy in managing acute ear pain.

Compositional Identity: Active Ingredients and Origin

The core chemical identity of Otidin is derived from its two synthetic active compounds. Phenazone (or Antipyrine) is classified as a pyrazolone derivative and is grouped with nonsteroidal anti-inflammatory drugs (NSAIDs), a class of medication known for reducing inflammation and pain. The second component, Tetracaine (also known as Amethocaine), is an ester-type local anaesthetic. Tetracaine is an established anaesthetic agent. This status underscores Tetracaine's role in medicine for providing localized numbing and pain relief. Both Phenazone and Tetracaine are chemically synthesized and are dissolved in an aqueous or hydro-alcoholic vehicle, confirming that the medicine is an externally applied liquid solution optimized for the ear canal.

Dual-Action Profile and General Purpose

The overall therapeutic profile of Otidin is defined by the dual-action synergy inherent in its composition, targeting two pathways of discomfort simultaneously. This specific combination is primarily positioned for use in typical scenarios where pain is accompanied by localized swelling. The role of the Tetracaine component is to provide rapid analgesia through localized nerve signal interruption, while the Phenazone component exerts an anti-inflammatory effect by reducing the presence of chemical mediators associated with swelling. The general purpose of this specific topical combination is to offer efficient and localized symptomatic relief for acute pain and associated inflammation confined to the ear.

Regulatory References

  1. WHO Essential Medicines: Tetracaine
  2. WHO Essential Medicines

What side effects are possible with Otidin?

Possible Side Effects and Safety Information

The official regulatory safety profile for Otidin (Phenazone/Tetracaine otic solution) is primarily characterized by localized adverse reactions at the administration site and critical safety restrictions, consistent with its topical use. The documented adverse reactions are formally classified as having an Unknown frequency in regulatory documents, meaning a definitive incidence rate has not been established.


Adverse Reactions and Organ Classification

Adverse reactions listed in official labeling are mainly confined to two System-Organ Classes:

  • Skin and Subcutaneous Tissue Disorders: This includes potential skin eruptions and hypersensitivity (allergic) reactions.
  • General Disorders and Administration Site Conditions: This covers localized symptoms around the ear canal, such as itching, soreness, and discomfort.

Hypersensitivity reactions are documented and considered a potentially serious adverse event. A critical safety note is the restriction against prolonged use, indicating a duration-related safety constraint.


Key Safety Restrictions and Special Populations

Certain constraints and contraindications are explicitly defined in the regulatory safety information:

  • Contraindications: The medicine is contraindicated if there is a known allergy to Phenazone, Tetracaine, or similar local anaesthetics. Furthermore, the solution must not be used if the tympanic membrane (eardrum) is perforated (burst), as this presents a significant safety risk.
  • Special Populations: The use of Otidin is prohibited in premature babies. For pregnancy and breastfeeding, regulatory documents state that the safety of the medicine has not been established.

This structured safety information outlines the documented official risks and specific limitations of use based strictly on government-approved labeling.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation defines the overdose profile of Otidin (Phenazone/Tetracaine) through the potential for rapid, severe systemic toxicity following accidental ingestion or use with a non-intact eardrum. Overdose manifestations are primarily characterized by the acute toxicity of the component agents.


Documented Overdose Manifestations

System Documented Clinical Manifestations
Neurologic Initial restlessness and tremors, progressing to convulsions, profound CNS depression, and coma.
Hematologic Signs of Methemoglobinemia, including cyanotic skin discoloration or abnormal blood coloration.

Emergency Regulatory Actions

Immediate medical help is strictly required due to the potential for a rapid, life-threatening progression of symptoms, including cardiac arrest and respiratory depression. The regulatory label mandates that individuals seek medical attention immediately or contact emergency services for any suspected overdose or accidental ingestion. Accidental ingestion resulting in death has been reported in children.

Treatment is primarily symptomatic and supportive. While no specific antidote is known for general systemic toxicity, specific supportive measures such as the administration of activated charcoal and intensive support of cardiovascular-renal function are described in the official overdose management guidance. Hospital monitoring is required for intensive supportive care.

Therapeutic Uses of Otidin

What Otidin Treats: Main Uses and Benefits

Otidin is primarily used to provide supportive symptomatic relief for distressing manifestations of acute ear conditions. It is relevant for easing common symptom clusters related to inflammatory or irritative states, including localized pain, discomfort, and swelling in the external auditory canal and middle ear. It is commonly used across conditions presenting with acute episodes, such as acute otitis media and acute external otitis, where it serves to ease pain associated with these states.

It is applied in scenarios where additional management of discomfort is needed, particularly during acute or disruptive episodes where symptoms interfere with daily functioning. The symptomatic support offered helps patients cope more steadily with difficult episodes and contributes to easing the overall symptom load.

“The symptomatic relief provided by Otidin supports general well-being during symptomatic phases of ear discomfort.”


Quick Fact: Therapeutic Focus: Localized Pain and Swelling

Regulatory References

  1. Israeli Ministry of Health's official drug registration document

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Otidin

Official regulatory documents strictly define the patient population eligible to use Otidin (containing Antipyrine and Tetracaine HCl) and list specific conditions for which its use is prohibited.


Populations for Whom Use is Prohibited (Contraindications)

Contraindication Domain Description
Tympanic Membrane Integrity Use is contraindicated in the presence of a perforated, ruptured, or injured eardrum or if there is any fluid discharge from the ear.
Hypersensitivity Use is contraindicated for individuals with a known allergy or sensitivity to the active ingredients (Antipyrine and Tetracaine HCl) or any other component in the formulation.

Eligibility Restrictions and Special Considerations

  • Pregnancy and Lactation: Safety for use in pregnant or lactating females has not been established, and these populations are typically excluded from product use unless a healthcare professional determines the benefit clearly outweighs potential risks.
  • Age-Related Use: While commonly used in both adults and children, specific safety and effectiveness for use in all pediatric age groups may not be fully established and often requires consultation with a healthcare professional.

In summary, the most critical regulatory constraint defining eligibility is the requirement for an intact eardrum to prevent the drug from contacting the middle ear structures. The medicine should only be used in the absence of a known allergy to its components.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile for Otidin (Phenazone/Tetracaine otic solution) based on documented prohibitions and pharmacokinetic considerations related to its active components.


Interaction Restrictions and Constraints

Category Official Regulatory Statement
Formal Contraindications Sulphonamide medicines (such as those used for infection or diabetes) are strictly contraindicated due to the risk of metabolic antagonism, as Tetracaine is metabolized into a substance that may inhibit the action of Sulphonamides. Co-administration with other ester-type local anaesthetics is also contraindicated due to hypersensitivity risk.
Population Constraint The product should be avoided in premature babies due to the immaturity of the enzyme system required to metabolize the Tetracaine component.
Substance Restriction The Phenazone component may lead to positive results in formal anti-doping tests, a relevant substance restriction noted in regulatory texts.

Pharmacokinetic Interaction Potential

Regulatory labels acknowledge that oral Phenazone is known to affect the metabolism of drugs broken down by liver enzymes. However, the official documentation includes the constraint that this pharmacokinetic interaction potential is considered to have minimal clinical relevance due to the expected low systemic absorption of the drug from its topical otic route of administration. No mandatory timing separation rules are documented for co-administration with other ear medicines.

Mechanism of Action

️ Peripheral Nociceptive Signal Blockade

The Tetracaine component acts directly on the voltage-gated sodium channels ( Na^+ channels) of peripheral nerve endings. By stabilizing these channels in an inactive state, the drug initiates a mechanistic cascade that inhibits the influx of sodium ions, preventing nerve depolarization and the generation of an action potential. This action results in localized inhibition of signal propagation in sensory fibers.


Inflammatory Mediator Synthesis Suppression

The Phenazone component exerts a slower, sustained biochemical action by inhibiting the enzymes Prostaglandin G/H Synthase ( COX-1 and COX-2). This non-selective inhibition suppresses the Arachidonic Acid Cascade, leading to reduced synthesis of pro-inflammatory prostaglandins. The resulting physiological effect is the modulation of prostaglandin-mediated responses, which affects local fluid dynamics and neuronal excitability.


Dual-Action Mechanistic Synergy

The drug’s overall physiological action is defined by the dual-action synergy of its components, which coordinate a rapid signal blockade with sustained mediator suppression. The mechanism is physiologically constrained to topical application; its functional activity requires the tympanic membrane to serve as the necessary anatomical barrier for localized action.

Dosage and Administration Information

Administration Methods for Otidin

Otidin is typically formulated as an otic solution intended for topical application within the ear canal. The process of administration requires careful handling to ensure the solution reaches the affected area effectively while maintaining the sterility of the product.

Preparation and Handling

Before application, the container is often held in the hands for several minutes. This allows the solution to approach body temperature, which may reduce the potential for vertigo or discomfort that can occur when cold liquids are introduced into the ear canal.

To maintain the integrity of the solution, the tip of the dropper or bottle must not come into contact with any surface, including the ear, fingers, or other objects. This precaution is taken to prevent microbial contamination of the remaining liquid.

Positioning for Application

The individual receiving the drops should be positioned with the affected ear facing upward. This is usually achieved by lying on one's side or tilting the head toward the opposite shoulder.

  • For adults: The outer ear is generally pulled gently upward and backward to straighten the ear canal.
  • For children: The outer ear may be pulled downward and backward to ensure the drops can travel down the canal.

After Application

Once the drops are placed into the ear, the individual should remain in the tilted position for a several minutes. This period of stillness allows the solution to settle and penetrate the ear canal. In some instances, a small piece of sterile cotton may be loosely placed at the opening of the ear canal to prevent the solution from leaking out, though this depends on the specific requirements of the treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Otidin


Evidence for Symptomatic Relief of Ear Ache/Pain in Acute Otitis Externa (AOE)

Research exploring Otidin’s use in the context of Acute Otitis Externa (AOE) primarily was evaluated in short-term, randomized, controlled clinical trials (RCTs). These studies focused on adult patients diagnosed with AOE who presented with specific outcomes related to physical discomfort that were then measured, such as ear ache. Researchers monitored how symptoms changed over time, specifically measuring reductions in patient-reported pain scores and assessing the healing process of the external ear canal by medical experts.

Studies reported how symptoms evolved in the observed populations during the short-term treatment period, which typically lasted around seven to ten days. Research also focused on local tolerance, where findings describe how patients reported their experience and any discomfort at the application site. These studies help show what has been observed so far under specific, controlled research conditions.


Evidence for Relief of Severe Ear Aches Caused by Outer Ear Inflammation

The evidence for Otidin’s evaluation in the context of severe ear aches caused by outer ear inflammation often overlaps with the research conducted for AOE. Studies exploring this specific use were evaluated in research settings involving fluctuating or acute symptom patterns. The research focused on outcomes related to physical discomfort and was designed to examine temporary physiological imbalance and the speed of symptom change.


Long-Term Studies and Follow-Up Duration

The majority of research conducted on Otidin focused on short-term symptom relief. Therefore, the long-term effects are not fully established. Evidence is limited regarding the durability of any reported short-term changes after the treatment course is finished. Certainty remains low regarding maintenance outcomes or the impact of repeated use over a long period.


Evidence in Specific Patient Populations

Research conducted on Otidin was concentrated on general adult populations. Data for certain groups remain insufficient, particularly for pediatric populations (children and infants). Similarly, comparative evidence is lacking for older adults (e.g., ages 65 and over). The available evidence for these special populations is limited.


What Is Still Uncertain About Otidin Research

The current evidence landscape for Otidin still contains significant research limitations. Follow-up durations were limited across many key studies, and sample sizes were modest in some instances. Comparative evidence is lacking for direct, head-to-head comparisons against all similar currently available treatment options.

Frequently Asked Questions (FAQ)

Common questions about Otidin (FAQ)

Q: Can Otidin cause dizziness or affect balance?

A: Official adverse reaction lists for the otic solution (ear drops) generally do not list dizziness or effects on balance as common side effects. The product is administered topically and is designed for minimal absorption into the body. However, some regulatory labels for the systemic components mention dizziness, which is why it is noted as a potential consideration, though the systemic risk is considered low with ear drops.

Q: Does Otidin treat ear infections caused by fungi?

A: Otidin is classified as a topical analgesic (pain reliever) and anti-inflammatory drug. According to its official indications, it is used for the symptomatic relief of painful conditions, such as acute otitis. Regulatory documents do not typically indicate or list the product as an antifungal agent for treating fungal ear infections.

Q: Are there any specific food or drinks I should avoid while using Otidin?

A: Official product information suggests there are typically no known interactions with food or drinks for this medication. Because the medicine is applied directly into the ear canal, the amount that enters the bloodstream is expected to be very low, limiting the potential for systemic interactions.

Q: What scientific evidence supports the effectiveness of Otidin for its stated uses?

A: The effectiveness of Otidin is supported by clinical studies that focus on its intended use as a topical pain reliever and anti-inflammatory agent. Regulatory approvals are based on data showing its ability to provide short-term symptomatic relief from ear pain and inflammation in conditions like acute otitis.

Q: Why is Otidin sometimes applied in the doctor's office instead of at home?

A: A critical safety requirement for using Otidin is having an intact eardrum. Healthcare providers may choose to administer the first dose themselves to ensure the eardrum is intact, which is a required prerequisite for use. This practice helps ensure the medicine is used safely and only in appropriate clinical conditions.

Q: Can Otidin cause a temporary change in hearing clarity?

A: Official safety data lists adverse reactions that are mainly localized, such as itching, soreness, and discomfort in the ear canal. While there is no direct, common report of changes in hearing clarity, severe localized reactions or the presence of the fluid in the canal could temporarily affect hearing. Any concerns about changes in hearing should be discussed with a healthcare professional.

Q: Is Otidin safe for use during pregnancy or while breastfeeding?

A: Official documents often state that the safety of Otidin for use during pregnancy and breastfeeding has not been definitively established. Some regulatory bodies suggest that due to its topical use and negligible systemic exposure, it may be used if a healthcare professional determines the benefit outweighs any potential risk. Use in these populations should be discussed with a healthcare professional.

Q: What is the maximum number of consecutive days Otidin should be used?

A: The recommended use of Otidin is for short-term, acute episodes only. According to official guidelines, treatment duration is generally limited to around 7 to 10 days. Medical review is necessary if symptoms do not improve within a few days of beginning treatment.

Q: Is it normal for the Otidin dropper tip to touch the ear during application?

A: Official administration instructions emphasize avoiding contamination of the dropper tip, meaning contact with the ear or any surface is generally discouraged to maintain hygiene. This prevents germs from potentially being introduced into the medication bottle.

Q: Are there any known interactions between Otidin and allergy medications?

A: Official labeling generally indicates a low potential for systemic drug interactions because minimal amounts of the medication are absorbed into the body from the ear. However, the use of Otidin is strictly prohibited with certain drugs, such as sulphonamide medicines and other ester-type local anaesthetics.

Q: Can Otidin be used for conditions other than ear problems?

A: Otidin is specifically formulated and indicated as an otic solution (ear drops) for local symptomatic treatment of certain painful conditions of the ear. It is not approved or intended for use on other parts of the body.

Q: Can Otidin interact with blood thinners or heart medications?

A: The potential for significant systemic drug interactions with drugs like blood thinners or heart medications is considered low due to the topical application and minimal systemic absorption of Otidin. However, one of its components, Phenazone, is known to interact with certain medications when taken orally; this potential interaction is mentioned in the systemic context; however, regulatory documents indicate the risk is considered minimal with the otic solution due to low systemic absorption.

Q: Can Otidin be used to treat itching in the ear?

A: Otidin is indicated for the symptomatic relief of pain and inflammation. While the medicine does contain an anti-inflammatory component, itching is sometimes listed in regulatory documents as a local adverse reaction or a sign of a hypersensitivity response, rather than a condition the medicine is intended to treat.

Q: Are there any studies comparing the long-term safety of Otidin?

A: Official research summaries indicate that most clinical studies conducted on Otidin focused on short-term relief, typically over a period of seven to ten days. Consequently, evidence for the long-term effects, safety, or durability of outcomes after the treatment course is generally limited or not fully established.

Q: What should I do if the Otidin solution looks cloudy or discolored?

A: Official documents describe Otidin as a clear liquid, which may be colorless or slightly yellow-brown. If the solution appears significantly cloudy or discolored, it may indicate a change in the product's quality or integrity. Any concerns regarding changes in the product's appearance should be discussed with a healthcare professional before use.

Q: How quickly should I expect to feel relief after starting Otidin?

A: The Tetracaine component of Otidin is a local anaesthetic intended for rapid nerve signal blockade. This mechanism suggests that localized pain relief (a numbing effect) is generally quick, though a precise onset time is not consistently specified in regulatory documents.

Q: What are the most commonly reported mild side effects of Otidin?

A: Official documents list localized symptoms at the administration site as the most frequently reported adverse reactions. These include local itching, soreness, discomfort, and potential skin reactions in or around the ear canal, although the official frequency is often categorized as 'Unknown'.

Q: Is it normal to feel a temporary stinging or burning sensation when applying Otidin?

A: Official adverse reaction lists include localized discomfort and soreness in the ear canal as possible effects of the solution. While stinging or burning are specific sensations, they may fall under the general categories of localized discomfort or irritation mentioned in the safety information.

Q: What happens if I accidentally miss a dose of Otidin?

A: Patient instructions found in official drug leaflets typically advise against taking a double dose to compensate for the one you missed. If a dose is missed, the recommended approach is generally to resume the regular dosing schedule with the next planned application.

How should Otidin be stored and disposed of?

The official regulatory requirements govern the storage, handling, and disposal of Otidin ear drops to ensure product stability and prevent unintentional exposure.

Storage & disposal scope

Storage/Disposal Aspect Official Regulatory Requirement
Labeled storage temperature Store below 25 C.
Stability after opening Maximum of 3 months after the bottle is first opened, but not past the package expiry date.
Handling requirements Wipe the dropper tip with a clean tissue and close the bottle tightly after use to prevent contamination.
Child-protection storage Keep out of the reach and sight of children and/or infants in a closed place.
Disposal instructions Do not throw away via wastewater or household waste; ask the pharmacist for guidance to protect the environment.

Storage/disposal classifications (high-level)

Classification Detail
Storage condition type Controlled room temperature ( below 25°C).
In-use stability classification Limited shelf-life after opening (3 months).

Connection to the overall storage/disposal profile: Regulatory documents mandate specific environmental controls, primarily a temperature cap of 25 C, to maintain the product's integrity. These rules include a strict 3-month post-opening stability period and instructions for dropper hygiene and securing the cap. Furthermore, the official labeling explicitly prohibits disposal through household waste or wastewater, requiring consultation with a pharmacist for environmentally appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Otidin found in:

A-Z Index: